In the Journals

Accommodative bioanalogic IOL provides good range of vision, long-term stability

A new-generation IOL yielded satisfactory near, intermediate and distance visual acuity with high stability, according to study findings.

The prospective study included 50 eyes of 25 patients. All patients underwent phacoemulsification with bilateral implantation of the Wichterle Intraocular Lens-Continuous Focus accommodative bioanalogic IOL (Medicem) through a 2.8-mm clear corneal incision on the steep axis of the cornea. Mean follow-up was 11.44 months.

Monocular uncorrected distance visual acuity improved significantly, according to the researchers, from 0.31 to 0.74 (P < .05). Monocular corrected distance visual acuity also improved markedly, from 0.61 to 0.82 (P < .05).

No eyes lost lines of CDVA; 88% of patients gained one line or more of CDVA.

Seventy-two percent of patients had uncorrected intermediate and near visual acuity of J2 or better at 1 year.

No intraoperative or postoperative complications were reported; posterior capsule opacification was reported in two eyes (4%) at 1 year.

Disclosure: The authors have no relevant financial disclosures.

A new-generation IOL yielded satisfactory near, intermediate and distance visual acuity with high stability, according to study findings.

The prospective study included 50 eyes of 25 patients. All patients underwent phacoemulsification with bilateral implantation of the Wichterle Intraocular Lens-Continuous Focus accommodative bioanalogic IOL (Medicem) through a 2.8-mm clear corneal incision on the steep axis of the cornea. Mean follow-up was 11.44 months.

Monocular uncorrected distance visual acuity improved significantly, according to the researchers, from 0.31 to 0.74 (P < .05). Monocular corrected distance visual acuity also improved markedly, from 0.61 to 0.82 (P < .05).

No eyes lost lines of CDVA; 88% of patients gained one line or more of CDVA.

Seventy-two percent of patients had uncorrected intermediate and near visual acuity of J2 or better at 1 year.

No intraoperative or postoperative complications were reported; posterior capsule opacification was reported in two eyes (4%) at 1 year.

Disclosure: The authors have no relevant financial disclosures.